Avoro Capital Advisors NGNE Position
Exited11-Fund ConvergenceAvoro Capital Advisors exited their position in Neurogene Inc. (NGNE) in Q4 2024, after holding the stock for 3 quarters.
The position was first reported in Q2 2024 and has been tracked across 3 quarterly 13F filings.
NGNE is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout in 959 days (Nov 30, 2028), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 31.2% of float with 18.9 days to cover, indicating significant bearish positioning against the stock.
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Full company profile →Short Interest
31.2%
18.9 days to cover
Avoro Capital Advisors NGNE Position History
Frequently Asked Questions
Does Avoro Capital Advisors own NGNE?
No. Avoro Capital Advisors exited their position in Neurogene Inc. (NGNE) in Q4 2024. They previously held the stock for 3 quarters.
How many hedge funds own NGNE?
11 specialist biotech hedge funds currently hold NGNE, including EcoR1 Capital, RTW Investments, Redmile Group and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy NGNE?
Avoro Capital Advisors's position in NGNE was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's NGNE position increasing or decreasing?
Avoro Capital Advisors completely exited their NGNE position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NGNECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →